2D and 3D Printing – A new Trend in Pharmaceutical Manufacturing: Hype or Future? | KN 6694
VeranstaltungsortArcotel John F Berlin
Werderscher Markt 11
Tel.:+49 30 405046-0
Fax:+49 30 405046-100
Kursprogramm zum Download
This course is organized for scientists and decision makers who are interested in the possibilities of 2D and 3D printing in the pharmaceutical world.
The program includes in-depth information about available printing techniques as well as the production and current status of 2D and 3D printed drugs, medical devices, tissues, and organs. Finally, speakers from regulatory authorities and industry will give their opinion on regulatory considerations for these new technologies.
Goals of the workshop
Pharmaceutical (bio-)printing holds the promise of tailor made, highly individual dosage forms, implants and even tissues and organs. Within the last years, printing techniques and their application have been greatly improved. Reports in the media give the impression that artificial organs and individually printed dosage forms with specific release profiles and less side effects are close to the market introduction.
In this seminar, leading minds from academia, industry and regulatory authorities report the current status and hopes for pharmaceutical 2D and 3D (bio-)printing. Available printing techniques will be introduced and discussed in detail. Sessions cover the manufacturing of medical devicesvia 3D printing and legal aspects thereof as well as extensive information on tissue and organ printing. Recent achievements but also limitations in printed drug delivery systems are presented. The seminar ends with a session by speakers about the regulatory aspects of dosage form printing.
Julian Quodbach, Ph.D.
Julian Quodbach is a pharmacist by training and started his PhD in 2010 at the Institute of Pharmaceutics and Biopharmaceutics at the University of Düsseldorf under the supervision of Professor Peter Kleinebudde. He received his PhD in 2014 and began his work as postdoc in the group of Professor Jörg Breitkreutz. During his postdoc, he developed an automated control system for fluid bed processes. Currently, he is supervising three PhD students and several master students who work on the progression of pharmaceutical 3D printing as well as the use of PAT in granulation processes.
Lieven Baert, Ph.D.
Lieven Baert, Ph.D., M.B.A. Managing Director JALIMA PHARMA. Lieven has studied at the University of Ghent (Belgium) where he has obtained the degrees of Pharmacist, Industrial Pharmacist, Ph.D. in Pharmaceutical Technology and Master in Business and Administration. After a post doc at Merck Canada, Lieven has worked at Janssen Pharmaceutica for more than 10 years, where he held different positions, such as Manager Clinical Supplies, CM&C leader and Director Formulation group. Thereafter Lieven joined the sister company Tibotec where he became Senior Research Fellow/Vice President Early Development and Innovation. In 2007, Lieven was awarded the Johnson & Johnsons Philip B. Hoffman award for Scientists for his innovation work on novel dosage forms for anti-viral drugs. Lieven is inventor on 22 patents and is Flanders District of Creativity Fellow. Lieven started his own company “Jalima Pharma” in 2010.
|Students (full time)||178,00 €|